Decellularized Adipose Tissue Matrix for Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tissue-derived products, such as ALLODERM and STRATTICE, are not ideal for regeneration, repair, or augmentation of adipose-containing tissues, particularly when bulk tissue volume is removed, as they may not support tissue growth and regeneration effectively and can induce inflammation.
Innovation Solution
Development of adipose tissue products with a decellularized extracellular matrix and reduced lipid content, processed to retain structural integrity and promote tissue growth, revascularization, and regeneration, while minimizing inflammation, through methods including decellularization and lipid reduction, and optionally seeding with viable cells or adding growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If adipose tissue products with reduced lipid content are used, then inflammation is minimized and tissue regeneration is supported, but the surgical handling and manipulation difficulty increases
Solution Approach 1:
The patent applies parameter changes by controlling the lipid content within a specific range (20-70% of original content) rather than complete removal. This optimization of the lipid content parameter achieves a balance: sufficient lipid reduction to minimize inflammation and immune response, while maintaining enough lipid to preserve the soft, pliable characteristics necessary for surgical handling and manipulation of the adipose tissue matrix.
2Object-affected harmful factors
If decellularization is performed to remove cellular material, then immune response is reduced, but the structural integrity and tissue growth support may be compromised
Solution Approach 1:
The patent applies the extraction principle by selectively removing cellular material (cells, nuclei, and cellular debris) from the adipose tissue while preserving the extracellular matrix structure. This decellularization process eliminates immunogenic elements that would trigger immune responses, while the retained extracellular matrix maintains the structural framework necessary to support tissue growth and regeneration.
Solution Approach 2:
The patent creates a composite structure by combining decellularized adipose tissue matrix with controlled residual lipid content. This composite material integrates the immunologically inert decellularized matrix framework with residual lipid that provides structural support and signaling functions, achieving both reduced immune response and maintained tissue growth support capability.
3Object-affected harmful factors
If lipid content is reduced to minimize inflammation, then the scaffold structure for cell migration may be weakened, but complete lipid removal is not necessary
Solution Approach 1:
The patent applies parameter changes by optimizing lipid content to a specific range (20-70% of original content) rather than complete removal. This controlled reduction maintains sufficient lipid to preserve the structural integrity and soft matrix characteristics needed for cell migration and tissue growth, while achieving sufficient lipid reduction to minimize inflammation and immune response.
Data Source
AI summary
The present disclosure provides tissue products produced from adipose-containing tissues, as well as methods for producing such tissue products. The tissue products can include decellularized and partially de-fatted tissues. In addition, the present disclosure provides systems and methods for using such products.